miR-29在白血病中的研究进展  

The research progress of miR-29 family in leukemia

作　　者：胡静宇[1,2] 何静[1] 陈燕[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院血液病研究所,武汉430022 [2]第四军医大学唐都医院,西安710038

出　　处：《临床血液学杂志》2017年第3期403-407,共5页Journal of Clinical Hematology

基　　金：国家自然科学基金资助(No:81300409)

摘　　要：microRNA是一种可控制基因表达的内源性非编码小分子单链RNA,由21~22个核苷酸组成,存在于多种生物体内。目前,人类基因组中已有1 424个microRNA得到证实[1]。成熟的单链microRNA与某些蛋白结合形成microRNA诱导的基因沉默复合物（miRISC）,miRISC中的microRNA通过与靶mRNA分子的3＇端非编码区域（3＇-UTR）互补,导致mRNA分子的降解或翻译受到抑制,从而控制基因转录后的表达调控。Summary MicroRNA is a class of small no-coding RNA comprising of 21-22 nucleotides,which plays a sig- nificant role in cell proliferation, differentiation, apoptosis and other physiological phases. A lot of researches indi- cate that abnormal expression of microRNA is associated with tumorigenesis and progression. Studies about mi- croRNA in leukemia grow fast in recent years. The dysregulated expression of microRNA directly contributes to hematological malignancies,such as acute myeloid leukemia （AMID, chronic lymphocytic leukemia （CLL） and so on. The miR-29 family contains miR-29a,miR-29b and miR-29c. Studies have shown that the aberrantly expression of miR-29 family influence the tumorigenesis, progression and prognosis. It plays a role of oncogenesis or tumor su- pression and may serve as the potential therapy targets of leukemia. In this review, the genetic structure of miR-29 and its regulation mechanism in leukemia are discussed.

关 键 词：MICRORNA MIR-29 白血病 

分 类 号：R733.7[医药卫生—肿瘤]